Bristol-Myers Squibb
Bristol-Myers Squibb is a global biopharmaceutical company focused on the discovery, development, and delivery of transformational medicines for patients facing serious diseases. The company combines the scale of a major pharmaceutical firm with the innovation-driven focus of biotechnology to address high-need therapeutic areas including oncology, hematology, immunology, and cardiovascular health.
Financials
Based on Q1 2026 filing
Revenue
View metricGross Profit
View metricNet Income
View metricOperating Cash Flow
View metricFree Cash Flow
View metricEPS (Diluted)
View metricBusiness Segments
Biopharmaceuticals
primaryA single integrated segment focused on the full lifecycle of drug development, from initial discovery and clinical licensing to global manufacturing and distribution of specialized medicines.
Eliquis, Opdivo, Revlimid, Pomalyst, Orencia, Sprycel, Yervoy, Abecma, Breyanzi, Camzyos, Sotyktu
Wholesalers, Specialty pharmacies, Hospitals, Clinics, Government agencies
Segment Financials
Eliquis — Percentage of reimbursement for development costs from alliance partner
View metricNorth America — Royalty rate due to regulatory approvals
View metricRest of World Except Japan, South Korea and Taiwan — Royalty rate due to regulatory approvals
View metricBusiness Overview
Competitive Position
A leading global biopharmaceutical entity with a dominant presence in oncology and cardiovascular medicine, characterized by high R&D investment and strategic acquisitions.
Geographies
United States, Switzerland, Ireland, Netherlands, Global
Customer Segments
Healthcare providers, Pharmaceutical distributors, Public health systems
Upstream Dependencies
Raw chemical suppliers, Contract research organizations, Academic research institutions, Biotech licensing partners
Downstream Customers
Drug wholesalers, Retail pharmacies, Medical centers, Government health programs
Competitors & Partners
Competitors
Merck & Co.
MRK
Direct competitor in oncology and immunotherapy
Pfizer
PFE
Competitor in oncology and cardiovascular treatments
Johnson & Johnson
JNJ
Competitor in immunology and cardiovascular segments
Gilead Sciences
GILD
Competitor in oncology and cell therapy
Revolution Medicines, Inc.
RVMD
Developer of KRAS(OFF) G12C inhibitor adagrasib
Subsidiaries
Celgene Corporation
Major oncology and hematology subsidiary
Bristol-Myers Squibb FAQ
Common questions about Bristol-Myers Squibb
Bristol-Myers Squibb is a global biopharmaceutical company focused on the discovery, development, and delivery of transformational medicines for patients facing serious diseases. The company combines the scale of a major pharmaceutical firm with the innovation-driven focus of biotechnology to address high-need therapeutic areas including oncology, hematology, immunology, and cardiovascular health.
Bristol-Myers Squibb (BMY) has a market capitalization of $121.42B and trades on NYSE.
Bristol-Myers Squibb generated $48.5B in trailing twelve-month revenue with net income of $7.3B, representing a net margin of 15.0%. Gross margin stands at 70.5%, with free cash flow of $11.9B. These figures are based on the Q1 2026 filing.
Bristol-Myers Squibb's key competitors include Merck & Co., Pfizer Inc., Johnson & Johnson, and others. These companies compete in similar markets and product categories.
Bristol-Myers Squibb has approximately 34,100 employees.